Skip to content
drillr.ai
Sign up

VTRS

Viatris Inc.

NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US

$16.88
−0.35%
Ask drillr

  • Sep 1, 2026, 14:30 UTC

    The Supreme Court of India upheld the Telangana High Court's decision not to initiate contempt proceedings against IQuest Enterprises Pvt. Ltd., ruling that a clarificatory statement made before a court does not constitute a binding undertaking for contempt purposes.

    Source:

  • Aug 28, 2026, 10:00 UTC

    Shield Therapeutics announced it will assume full commercial control of ACCRUFeR in the US from Viatris starting 30 September, without an upfront cash payment, in exchange for a reduced royalty on US net sales over five years.

    Source:

  • Aug 6, 2026, 21:43 UTC

    Viatris Inc shares fell 7.6% on August 6, 2026, closing at $16.29.

    Source:

  • Aug 6, 2026, 10:59 UTC

    Viatris returned approximately $550 million of capital to shareholders, including through share repurchases.

    Source:

  • Aug 6, 2026, 10:59 UTC

    Viatris announced the sale of global rights to Tyrvaya.

    Source:

  • Aug 6, 2026, 10:59 UTC

    Viatris reported second-quarter 2026 financial results with total revenues of $3.8 billion, a 5% reported growth compared to the second quarter of 2025, and a U.S. GAAP net loss of $119 million.

    Source:

  • Aug 4, 2026, 10:59 UTC

    Viatris Inc. announced that its Board of Directors declared a quarterly dividend of $0.12 per share, payable on September 16, 2026, to shareholders of record as of August 21, 2026.

    Source:

  • Aug 3, 2026, 23:59 UTC

    Nebraska and a bipartisan coalition of state attorneys general finalized settlements with eight generic opioid manufacturers, providing up to $3,082,987 for opioid remediation in Nebraska and imposing marketing restrictions and monitoring requirements.

    Source:

  • Jul 29, 2026, 10:59 UTC

    The U.S. FDA approved Viatris's Gwyn Lo contraceptive patch.

    Source:

  • Jul 2, 2026, 17:51 UTC

    Knoa Pharma appointed Michael Goettler as its CEO and president.

    Source:

  • Jul 1, 2026, 00:00 UTC

    Viatris Inc. entered into an amended and restated ¥40 billion senior unsecured term loan credit agreement with Mizuho Bank, MUFG Bank, and Sumitomo Mitsui Banking Corporation, refinancing its original 2021 facility for general corporate purposes.

  • Jun 29, 2026, 10:59 UTC

    Viatris announced positive top-line results from a Phase 3 study of VR-205 in Japanese adults with primary IgA nephropathy.

    Source:

  • Jun 18, 2026, 00:00 UTC

    Viatris Inc issued €650 million of 4.250% senior unsecured notes due 2033, guaranteed by three subsidiaries, with net proceeds to repay maturing 2026 senior notes and for general corporate purposes.